For this reason, HRT should not be carried out after RRSO in premenopausal BRCA1/2-pV carriers or of carriers of pV other breast and/or ovarian cancer genes or genes of the Lynch-syndrome after diagnosis of breast cancer. This evidence concerns the gene BRCA1 and ovarian carcinoma.